Adjuvant chemotherapy for bladder cancer

Expert Review of Anticancer Therapy

Volumn 5, Issue 6, 2005, Pages 987-991

  Sternberg, Cora N ^a   Calabró, Fabio ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Adjuvant chemotherapy; Infiltrating bladder cancer; Meta analysis; Radical cystectomy; Randomized controlled trials

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; PROTEIN P53; VINBLASTINE;

BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CYSTECTOMY; DRUG DOSE REDUCTION; DRUG MEGADOSE; HUMAN; LEUKOPENIA; META ANALYSIS; OCCULT CANCER; POSTOPERATIVE CARE; REVIEW; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; HUMANS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; SURVIVAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 29844455994     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.6.987     Document Type: Review

References (29)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16(3), 481-488 (2005).
2. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001).
3. Dalbagni G, Genega E, Hashibe M et al. Cystectomy for bladder cancer: a contemporary series. J. Urol. 165(4), 1111-1116 (2001).
4. Bassi P, Ferrante GD, Piazza N et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J. Urol. 161(5), 1494-1497 (1999).
5. Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J. Urol. 158(2), 393-399 (1997).
6. Sternberg CN. Neo-adjuvant and adjuvant chemotherapy of bladder cancer: is there a role? Ann. Oncol. 13(Suppl. 4), 273-279 (2002).
7. Sternberg CN. Current perspectives in muscle invasive bladder cancer. Eur. J. Cancer 38(4), 460-467 (2002).
8. de Braud F, Maffezzini M, Vitale V et al. Bladder cancer. Crit. Rev. Oncol. Hematol. 41(1), 89-106 (2002).
9. Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol. 145, 459-467 (1991).
10. Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 nad pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy results of a controlled prospective study. J. Urol. 148, 302-307 (1992).
11. Stockle M, Meyenburg W, Wellek S. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J. Urol. 153, 47-52 (1995).
12. Otto T, Börgemann C, Krege S et al. Adjuvant chemotherapy in locally advanced bladder cancer (PT3/PN1-2,M0) - a Phase III study. Eur. Urol. 39(Suppl. 5), 147 (2001).
13. Studer UE, Bacchi M, Biedermann C. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J. Urol. 152, 81-84 (1994).
14. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol. 155(2), 495-499 (1996).
15. Bono AV, Benvenuti C, Gibba A et al. Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol. Ital. 11, 5-8 (1997).
16. Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: What we do not know and why. Ann. Oncol. 11(7), 851-856 (2000).
17. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol. 48(2), 189-201 (2005).
18. Shearer RJ, Chilvers CF, Bloom HJ, Bliss JM, Horwich A, Babiker A. Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Br. J. Urol. 62(6), 558-564 (1988).
19. Richards B, Bastable JR, Freedman L et al. Adjuvant chemotherapy with doxorubicin (Adriamycin) and 5-fluorouracil in T3, NX, MO bladder cancer treated with radiotherapy. Br. J. Urol. 55(4), 386-391 (1983).
20. Einstein AB Jr, Shipley W, Coombs J, Cummings KB, Soloway MS, Hawkins I. Cisplatin as adjunctive treatment for invasive bladder carcinoma: tolerance and toxicities. Urology 23(4 Suppl), 110-117 (1984).
21. Lehmann J, Retz M, Wierners C et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, Phase III trial (AUO-AB 05/95). J. Clin. Oncol. 23(22), 4963-4974 (2005).
22. Galsky MD, Scher HI. Bladder cancer 'adjuvant-lite': tastes great (works as well) and less filling (less toxic)? J. Clin. Oncol. 23(22), 4823-4826 (2005).
23. Sternberg CN, Yagoda A, Scher HI et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer 64, 2448-2458 (1989).
24. Sternberg CN, de Mulder PHM, Schornagel JH et al. Randomized Phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer. Protocol No. 30924. J. Clin. Oncol. 19(10), 2638-2646 (2001).
25. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068-3077 (2000).
26. Bellmunt J, de Wit R, Albiol S, Tabernero JM, Albanell J, Baselga J. New drugs and new approaches in metastatic bladder cancer. Crit. Rev. Oncol. Hematol. 2, 195-206 (2003).
27. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder. N. Engl. J. Med. 331(19), 1259-1264 (1994).
28. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 385(6612), 123-125 (1997).
29. Herr HW, Bajorin DF, Scher HI, Cordon-Cardo C, Reuter VE. Can p53 help select patients with invasive bladder cancer for bladder preservation? J. Urol. 161(1), 20-22 (1999).